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Abstract Sickle cell trait (SCT) is usually benign. However,
there are some conditions that may lead to SCT-related prob-
lems and put athletes with the trait at particular risk. In 2010
the National Collegiate Athletic Association (NCAA) issued a
policy that required all Division I (DI) student-athletes to con-
firm their SCT status or sign a liability waiver to opt out of
testing. Athletic trainers and team physicians play key roles in
the policy implementation and we examined their perceptions
and practices. Between December 2013 and March 2014 we
interviewed 13 head athletic trainers and team physicians at
NCAA Division I colleges and universities in North Carolina.
We used an interview guide with open-ended questions cov-
ering knowledge of SCT, historical screening and education
practices, current implementation, and policy benefits and
challenges. Participants were knowledgeable about SCT and
thought the policy was beneficial in providing SCT health
information to and for student-athletes. Schools varied in pro-
vision of genetic counseling, offering the waiver, SCT tests
administered, and other aspects. Challenges included: insuffi-
cient guidance from the NCAA; financial considerations; and
misunderstanding of the relationships of race and ancestry to
SCT risk. Athletic staff found the policy valuable, but felt it
needs clarity and standardization.
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Introduction
In 2010 the National Collegiate Athletic Association (NCAA)
proposed a sickle cell trait (SCT) screening policy in the wake
of the response and lawsuit that followed the death of anAfrican
American student-athlete who had SCT. This policy, approved
and implemented in 2010, required that all Division I (DI)
student-athletes beginning their initial season of eligibility and
all students trying out for a team confirm their SCT status by a)
undergoing a sickle cell solubility test, b) showing proof of prior
testing for the trait or, c) signing a liability waiver if the athlete
chooses to opt out of testing. The current NCAApolicy is one of
the largest SCT screening programs implemented by a private
entity in the United States, and has been controversial (Ojodu
et al. 2014; Tarini et al. 2012). While pre-participation physical
examinations are required of all NCAA student-athletes, and
pre-participation baseline concussion assessments are recom-
mended as best practice, SCT is the only specific condition for
which the NCAA requires a screening test. (J. Parsons, NCAA,
personal communication 2015).
SCT is characterized by the inheritance of one normal beta
hemoglobin allele and one sickle beta hemoglobin allele
(HbAS). SCT should not be confused with sickle cell anemia
caused by the inheritance of two sickle hemoglobin alleles
(HbSS), or other forms of sickle cell disease (SCD) that include
the combination of the sickle allele and other abnormal hemo-
globin alleles (e.g. HbSC or HbSβ-thal) (Tsaras et al. 2009).
These conditions are detected by routine state newborn screening
programs for early identification of those affected and in order to
prevent life-threatening infections and other causes of childhood
morbidity and mortality (Ojodu et al. 2014). Unlike SCD
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though, SCT status is typically not reported to families when
detected through newborn screening. SCD and SCT are most
common among people with ancestors from Sub-Saharan
Africa, the Mediterranean basin, India, the Arabian Peninsula,
the Caribbean, and South and Central America (The Sickle Cell
Disease Association of America 2015a). In the United States,
approximately 3million people carry SCT, and it occurs in about
8% of blacks, .5% of Hispanics, and .2% of whites (Bonham
et al. 2010;Kark et al. 1987; The Sickle Cell DiseaseAssociation
of America 2015a).
SCT was once thought to be a benign condition; however,
there is enough clinical evidence to suggest otherwise (Baskurt
& Meiselman 2007; Grant et al. 2011; Jung et al. 2011; Ojodu
et al. 2014; Tsaras et al. 2009). Complications that have been
associated with SCTare well documented (Caughey et al. 2014;
Folsom et al. 2015; Kark et al. 1987; Key & Derebail 2010;
Tsaras et al. 2009). Studies examining the relationship between
SCT and varying intensities of physical exertion, altitude, and
heat have shown that complications associated with SCT can
result in rhabdomyolysis, splenic infarction, pulmonary embo-
lism, and hyphema (hemorrhage of the eye), among other non-
traumatic injuries (Drehner et al. 1999; Gardner & Kark 1994;
Kark 2000; Mitchell 2007). While linkages have been made
with these complications, causation has not been established
(Aloe et al. 2011; Blinder & Russel 2014; Ferrari et al. 2015).
The conditions that may lead to SCT-related problems—
physical exertion, heat, and altitude—put athletes at particular
risk. From 2000 to 2010, ten deaths were attributed to complica-
tions of exertional sickling among football players while condi-
tioning (Eichner 2011). In 2011, Eichner estimated that approx-
imately 3% to 4% of all DI football players carry SCT, yet 63%
of all deaths in DI football during 2000–2010 were attributed to
SCT. A study by Harmon et al. (2012) illustrated that NCAA
football players with SCT have an exceptionally high risk of
exertional death (1:827), 37 times higher than those without the
trait. Yet prior to 2009, some screening for SCTwas conducted at
only half of the schools within the NCAA (Eichner 2010). In
addition to the exercise-related complications associated with
SCT, positive screening results have important reproductive im-
plications and should be discussed with a genetic counselor.
In 2010, North Carolina Agricultural and Technical State
University came under fire when a student-athlete recruit died
during track tryouts. Prior to death, the athlete did not have a
physical, a test to determine sickle cell trait status, or an NCAA
waiver for SCT testing: clearly a failure to implement the policy
(Witt 2010). As this tragic story shows, even though the NCAA
instituted the policy in 2010, some schools were not in compli-
ance. To date, implementation processes for the NCAA policy
have not been extensively studied. Researchers have surveyed
sports medicine providers, pediatricians, and college athletes
about their attitudes, concerns, and perceptions of the policy prior
to its implementation (Acharya et al. 2011; Koopmans et al.
2011; Lawrence & Shah 2014); however, there is no published
study on the implementation of the policy from the perspective of
those responsible for its implementation. All three divisions of
the NCAA have now adopted the SCT screening policy (Brown
2013; Hendrickson 2012; Stein 2010). Given the significance of
this policy for student-athletes with SCT and the fact that
Division I was the first to adopt it, we sought to gather informa-
tion from DI institutions in North Carolina, a state considered a
hotbed of college sports, about their implementation of the 2010
policy. Head athletic trainers and team physicians play key roles
in implementation. This paper examines their perceptions and
practices approximately three years after the policy took effect.
Methods
We conducted telephone interviews to assess the knowledge,
perceptions, and practices of head athletic trainers and team
physicians at NCAA DI colleges and universities in North
Carolina.We created a semi-structured interview guide designed
to collect information on: knowledge of SCT, historical screen-
ing and education practices, current implementation practices,
and perceptions of the benefits and challenges of the policy. We
piloted the draft guide with an assistant athletic director.
Participant Selection and Recruitment
Athletic staff at Duke University and project consultants rec-
ommended that we focus on head athletic trainers, since they
are primarily responsible for directing the implementation of
the policy, and on team physicians, as they deal with health
issues related to SCT.We contacted via email athletic directors
at the 18 NCAA DI colleges and universities in North
Carolina, via email, to ascertain their interest in their school’s
participation in the study. From those who expressed interest
we requested the contact information for head athletic trainers
and team physicians at their schools who were knowledgeable
about the policy and spent time with student-athletes. We con-
ducted 13 interviews by telephone between December 2013
and March 2014. Each participant received a $25 gift card.
Data Collection and Analysis Procedures
We digitally recorded each telephone interview with the par-
ticipant’s oral consent. Interviews lasted between 15 and
30 min. We labeled transcripts with code numbers to preserve
participant confidentiality. Interview recordings were tran-
scribed verbatim and then analyzed using NVivo 10 (NVivo
qualitative data analysis software; QSR International Pty Ltd.
Version 10, 2012), a qualitative analysis software program.
Basic coding structure reflected a priori themes in the inter-
view guide (Bernard & Ryan 2010). We wrote definitions for
the codes and created additional codes for emergent themes as
we analyzed the interviews in 2014–2015 (MacQueen et al.
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1998; Miles et al. 2013).We discussed any differences in code
assignment until we reached consensus. After coding the tran-
scripts, we reviewed the data at each code to determine if they
were covered by the code definition. We used a thematic anal-
ysis approach; examining the commonalities and differences
within the data as well as relationships among data categories
(MacQueen et al. 1998). We identified representative views of
the respondents as well as outliers, allowing us to more accu-
rately characterize the range of respondents’ experiences and
observations. All study procedures were reviewed and ap-
proved by the Institutional Review Board at Duke University.
Results
Characteristics of the Sample
We invited all 18 NCAADI colleges and universities in North
Carolina to participate in the study. Ten schools granted us
interviews and three of those schools had two participants
each, for a total of 13 interviews. Table 1 shows the charac-
teristics of the respondents. Of the 13 participants, three were
team physicians and the remainder were head athletic trainers.
The sex breakdown was ten males and three females. Ages
ranged from 31 to 63, with the average age being 43 years.
Athletic staff members had been in their current positions
from 1.5 to 30 years. Five were in their position for less than
five years; five were in their position for over 10 years.
Topics and Themes
Current Knowledge and Historical Practices
One of the aims of the study was to assess the athletic trainers’
and team physicians’ current knowledge of SCT and SCD,
including their awareness of the populations at risk and the
potential consequences of carrying SCT. We asked the
following questions: What causes sickle cell trait? What pop-
ulations are at risk for having sickle cell trait? What may
happen to people who have sickle cell trait? All of the 13 staff
interviewed responded. One participant did not demonstrate
any knowledge; 7 knew most of the information; and 5 knew
that SCT was genetic, that having SCT was different from
having SCD, that populations without African ancestry could
carry SCT; and that people may not know they have SCT
unless they have been tested. One athletic trainer explained:
Obviously, it’s an inherited trait. But you don’t have the
disease [SCD] but you have at least one gene for it. The
athletes can have a nice full career without any prob-
lems, but you just have to be aware of it. Most people are
obviously tested at birth, but we don’t know that test and
that’s why we’re doing all this stuff with the NCAA. But
usually a lot of people don’t know they have it because
they actually do fine with it.
Like this respondent, others alluded to newborn screening
at various points during the interviews. However, as onemight
expect, there was a lack of awareness among some respon-
dents about the availability of newborn screening results for
SCT. Many assumed families already knew those results. For
example, an athletic trainer asked, B…if you’re 17, 18 years
old you’ve already been competing at a high level, you’ve
played DI athletics. How could you not know what your
screening [status] is?^
We also observed that a few respondents repeatedly used
the term Bsickle cell athlete^ to refer to a student-athlete with
SCT. Individuals may have been using this as short hand for
Ba student-athlete with sickle cell trait^, and may be unaware
that the term is both misleading and potentially stigmatizing.
With regard to previous screening for SCT, 10 of the 13
respondents reported that their institutions did not screen ath-
letes for SCT before implementation of the policy, and that
SCT did not receive any attention from the athletic staff. Two
respondents indicated their schools had been screening some
athletes since 2008. One of these respondents described the
screening as follows:
Screening at that time [before the 2010 policy] was vol-
untary. Obviously it was part of our pre-participation
screening process, part of the physical exam, especially
for those student-athletes more than likely that would
have the sickle cell trait. We did not require official
sickle cell [trait] testing.
Opting Out
When creating the 2010 policy, the NCAA DI Legislative
Council offered a waiver in response to some NCAA
Table 1 Characteristics of Participants (N = 13)
N or Mean ± SD % or (95% CI)
Sex
Female 3 23.1%
Male 10 76.9%
Age (Years) 43.8 ± 8.8 (38.5, 49.1)
Job Title
Head Athletic Trainer 10 76.9%
Team Physician 3 23.1%
Racea
Black 2 15.4%
White 11 84.6%
aAs defined by 2010 U.S. OMB categories
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conferences that requested it (Bonham et al. 2010; Quick
2011). Of the 10 schools in our study, 3 allowed a waiver
and 6 did not. Responses from the 10th school were inconsis-
tent: the athletic trainer reported their school did not offer
waivers and the team physician stated they were provided.
One of the respondents who said that his school did not offer
the waiver explained, BWe did that [made waiver available]
for a year and then we moved [our stance]. It was really legal
[the legal department] who indicated they would prefer every-
one to be screened.^
Of the 3 schools that did allow a waiver, one did not par-
ticipate in football. Another school allowed the waiver only
for religious reasons. A staff member from this school report-
ed that despite offering the waiver, they captured the majority
of athletes: BLet me just say that 99% of the time our student-
athletes will get blood drawn. I can’t say in the last four years
we had absolutely 100%, but I know that for themost part they
have all, 99% have, complied.^ A head athletic trainer said he
did not have a problem offering the waiver, but that many of
the athletes Bjust go ahead and do it [get screened].^ When
asked for their specific reasoning behind the allowance of
waivers, he replied, BSome of them will [say], ‘Hey, I’m
white, I don’t think I have it. I don’t like needles.^
Race and Geographic Ancestry
While we did ask about the Brace^ of our respondents and
whether all athletes are screened (i.e. implementation of the
waiver), we did not ask directly about the racial classifications
of the athletes or how race may play a role in perceptions
around screening. Despite this, themes around race- or
ancestry-based risk associations emerged. When we asked
questions about general knowledge of SCT, many respondents
replied with answers that linked the sickle allele to African
ancestry and the diasporic population of blacks in America.
Some respondents also spoke specifically about geographic
regions where they thought there was a low risk of SCT being
present in the population.
In response to our question about the challenges of the
policy, an athletic trainer mentioned that a coach at his school,
who recruits student-athletes from certain geographic regions,
gives substantial pushback concerning the policy:
One in particular, he recruits primarily eastern European
females who are at the lowest risk category as possible
and he doesn’t understand why we’re requiring this
when they’re not at risk. He is not grasping that they
are at risk; it’s just very, very unlikely.
After asking a team physician about his university’s policy
on opting out, he referred us to the head athletic trainer, but
responded, BIf they can opt out I don’t have a problem with
that. Some Scandinavian kid, the risk is a little on the low side
shall we say.^
Benefits and Challenges of the Policy
Eight out of ten respondents indicated that the SCT screening
had benefits. The most common benefit mentioned was that
the knowledge of who had SCT enabled athletes to be aware
of the condition in themselves and in others, and helped staff
take steps to prevent potentially serious problems. A director
of athletic training described benefits as, BMore knowledge to
try to prevent tragic incidents. It’s another tool for us to try to
prevent something from happening. It’s also been educational
for all involved, about the risk of sickle cell trait.^ An athletic
trainer said, BI also have found student-athletes who didn’t
realize they were sickle cell [trait] positive, therefore I do think
there is certainly a positive merit to that [testing].^
In providing his perspectives on the benefits of the screen-
ing policy, one athletic trainer weighed the benefit of knowing
an athlete’s trait status against the cost of testing. His comment
was framed around race or ancestry:
I think it’s very reassuring to know who is or who is not
[positive for SCT]. I think that’s been fabulous, that we
have absolute certainty of who is or who is not [positive
for SCT] and the medical staff knows that and the
coaching staff knows that as well, and that’s been great.
The policy, we know there’s obviously a higher yield of
those who have sickle cell trait based upon their demo-
graphic. But it is quite honestly, we have such a small
number of student-athletes that have sickle cell [trait]
that it is a tremendous expense.
When we asked respondents specifically about challenges,
two reported none. Other participants cited many challenges
such as, insufficient information from the NCAA on how to
implement the policy, financial burden of test costs (especially
among the smaller schools), and some athletes not adhering to
training regimens. The most commonly reported challenge was
not getting the test results in time to clear athletes for practice.
Much confusion emerged around the perceived lack of di-
rection from the NCAA. A director of athletic training stated:
BIt’s not necessarily a mandatory screening because the ath-
letes were allowed to sign a waiver and waive out of it. So the
term mandatory was very confusing to people.^ In addition,
other respondents mentioned the lack of specific information
about how certain aspects of the policy should be executed,
such as the test required to screen for SCT. An athletic trainer
expressed this as follows:
NCAA is very vague about what they require; they just
say that it’s required. Because there’s a lot of different
tests, there’s no specific as to what test is required or
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what numbers you have to have or what the results have
to say. It’s just you have to be tested and you have to
have results.
Questions about the reasons behind the implementation of
the policy posed a challenge for some. Four respondents
expressed concern that the policy was primarily a reaction to
the 2008 lawsuit brought against the NCAA, and dismissed
the idea that the policy resulted from a genuine interest in the
health of student-athletes. A team physician stated, BI thought
it was completely ridiculous and all driven by [the] legal [de-
partment] and not medical, quite frankly.^ Others wondered
about the lack of testing for other potentially dangerous med-
ical conditions, such as heart problems.
Some respondents were concerned that athletes did not
understand the implications of having SCT. An athletic trainer
reported:
The only challenge is some student-athletes who never
had a problem, when you tell them they have sickle cell
[trait] and try to hold them to the training regimen they
feel like they don’t have a problem, there’s nothing
wrong with them, but they’ve got to–why they’ve got
to do the different regimen or why their regimen is al-
tered. They feel like nothing’s wrong with them because
they really don’t understand.
This quote from an athletic trainer aptly summarizes the
sentiments of multiple respondents regarding challenges of
the policy:
So while I think it’s a good idea on one side, obviously
it’s [SCT status] important information. The other side is
just how we implement the testing, importance, and how
soon canwe start athletics, andwhy does everybody have
to have it, what are the financial considerations. All those,
certainly I don’t think were well thought out, in my opin-
ion, before we instituted this. So I think that was some of
the frustration with myself [for me] and many of my
colleagues, is how you would implement this.
Discussion
Although some research has addressed the NCAA SCT
screening policy itself (Grant et al. 2011; Jordan et al. 2011;
Tarini et al. 2012; Thompson 2013), to our knowledge this is
the first published study to provide data obtained directly from
athletic staff with experience (3 years) implementing the pol-
icy. This study sheds light on staff perspectives and how the
policy might/may be executed at some DI colleges and uni-
versities. It presents evidence for several of the ethical,
societal, scientific, and practical considerations that other au-
thors predicted (Bonham et al. 2010; Grant et al. 2011; Jordan
et al. 2011; Thompson 2013), and will be useful to schools and
to the NCAA as they seek to enhance the benefits of the
screening program and address areas of concern.
The NCAA and some of the institutional athletic depart-
ments provided their athletic staff with educational materials
on SCT, and we found that almost all of our study participants
were knowledgeable. It is unknown where this knowledge
comes from and how consistent it is across schools.
Institutions may have different SCT education standards since
the NCAA does not require that student-athletes, coaches, and
trainers access any resource as part of the screening process
(Ferrari et al. 2015). In addition, the educational material avail-
able from the NCAA addresses the athletic impact of SCT; it
does not address the broader health and reproductive conse-
quences that a positive SCT screening result may have for both
the student-athlete and their family members (Bonham et al.
2010; Natowicz & Alper 1991). Athletic staff reported that
they, along with student-athletes, appreciated the increased
SCT knowledge. Some respondents assumed, however, that
parents, and thus student-athletes, would be aware of their
SCT status by the time they participate in DI sports programs.
State newborn screening programs test babies at birth for SCD,
and through this process also identify babies with SCT, mean-
ing they carry a hemoglobin S allele that they could pass on to a
child (Lane 2001; National Institutes of Health 2016).
Although every child in the US is presumably tested at birth,
most newborn screening programs are required to report only
SCD, not trait status. Additionally, newborn screening data are
incomplete and reporting procedures vary from state to state
(Ojodu et al. 2014). Due to the assumed benign nature of SCT
in clinical and public health discourse, many physicians who
do relay trait information to parents also often downplay the
potential consequences of the trait. Comprehensive education
about SCT (and SCD) should include information about accu-
rate and non-stigmatizing terminology to describe people with
these conditions. For example, the term^ sickler^ has histori-
cally been used in medical discourse to describe individuals
living with sickle cell disease. Members of this patient popula-
tion have voiced discomfort with this label and may view it as a
sign of disrespect (Bediako et al. 2016; Wailoo 2006). As a
general best practice, individuals should be trained to avoid
the attachment of medical characteristics to individuals.
Across the schools, the use of the waiver was inconsistent
and confusing. It appeared some schools and athletes were
using the waiver generously and frequently based on the per-
ception that only certain people were at risk of having SCT,
therefore it was unnecessary to test all student-athletes. The
NCAA SCT screening is designed to capture every student-
athlete that participates in a DI (and now DII and DIII) sport;
however, because many people mistakenly think SCT only
affects those with African heritage, the waiver potentially
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facilitates singling out and labeling black athletes as the only
ones for whom the policy was designed (Naik & Haywood
2015). None of the participants mentioned instances of stig-
matization or discrimination; however, many did mention
their frustration when the screening policy delayed the start
of training. This frustration was especially apparent when
student-athletes were thought to have low risk for the presence
of an S allele, yet could not practice until their test results came
in. There is certainly the potential for this frustration to lead to
lapses in compliance with the policy, whereby black student-
athletes are targeted and others easily allowed to opt out: thus
reinforcing stigma attached to blackness (Jenerette & Brewer,
2010; Wailoo 2006). Black student-athletes already potential-
ly face longstanding challenges such as racism and racial
stereotyping on predominantly white campuses (Njororai
2012). Additional research is needed to determine whether
the required screening fosters stigmatization and discrimina-
tion, or increased knowledge and impartial attitudes about
race- or ancestry-based risk.
Practice Implications
Along with noting personal, practical, and educational bene-
fits to both athletes and the staff themselves, study participants
identified several challenges related to the policy. A common
theme regarding challenges was the perception that the
NCAA’s lack of guidance left them unclear about the best
procedures for fulfilling the policy. As a result, staff employed
inconsistent practices across athletic programs. For example,
due to variation in the costs of tests for SCT status, schools
used different tests based on their budgets. Perhaps related to
test cost and lack of guidance from the NCAA, respondents
from only two of the 10 participating schools, mentioned that
genetic counseling was provided for students who tested pos-
itive. In their sports medicine handbook, the NCAA states that
if a student-athlete tests positive for SCT, he or she Bshould be
offered counseling on the implications of sickle cell trait, in-
cluding health, athletics participation and family planning
(National Collegiate Athletic Association 2014).^ There is
no clarification, though, on who should provide this counsel-
ing or how the costs should be covered, and it is evident from
our data that the counseling may not occur at all schools.
Thus, student-athletes may not be receiving adequate informa-
tion regarding the risks and benefits of testing in order to make
an informed decision to participate in testing (Ferrari et al.
2015). Determining an athlete’s trait status is not sufficient
to protect them from potential harm; the athlete must also
understand why screening is being done, and what the results
could mean. There are important implications of a positive
SCT test, and they extend beyond training and the athletic
field (Ferrari et al. 2015; Jordan et al. 2011). The solubility
test, which many schools use, only tests for hemoglobin S and
may not identify other variants, including thalassemia, which
can be passed to offspring. Those receiving positive SCT
test results should be provided with emotional support
and explanations of genetic information specific to an in-
dividual’s needs, interests, and circumstances. The NCAA
screening may be the first time student-athletes encounter
genetic testing, therefore comprehensive genetic counsel-
ing practices are recommended (Ferrari et al. 2015). Ferrari
et al. (2015) and others suggest that an Bopt in^ program by
the NCAA, instead of the current policy with the Bopt out
with waiver^ option, could address some of the policy’s
gaps and inconsistencies by following consistent, required
SCT education and offering counseling to all student-
athletes identified with SCT. This approach might also bet-
ter respect student-athletes’ autonomy and protect their pri-
vacy (Ferrari et al. 2015). In addition, organizations such
as The American Society of Hematology, Sickle Cell
Disease Association of America, and American College
of Sports Medicine have all advocated for genetic counsel-
ing for each individual who receives a positive screening
result to communicate information not only about possible
health risks, but also reproductive risks (American Society
of Hematology 2012; The Sickle Cell Disease Association
of America 2015b; Thompson 2013). Some schools are
incorporating genetic counseling into their screening pro-
gram and can serve as models for other schools (Ferrari
et al. 2015). Genetic counselors are essential because they
can provide accurate and appropriate information directly
to student-athletes and serve as resources for staff. Student-
athletes should be informed about possible results and their
implications, SCT symptoms and implications for health,
NCAA-recommended precautions related to athletic and
physical exertion, and reproductive and familial signifi-
cance of SCT (passing on an abnormal allele to a child,
reproducing with another SCT carrier thus increasing the
chances for the child to have SCD) (Ferrari et al. 2015).
This study reveals ethical issues around screening that have
yet to be resolved. If screening is mandatory, issues such as
autonomy, beneficence and privacy need to be carefully con-
sidered and addressed for this policy to be ethically appropri-
ate (Aloe et al. 2011). The existing program raises concerns
about the autonomy of student-athletes’ decision-making and
the schools’ ability to satisfy the requirements of informed
consent for medical testing without appropriate genetic
counseling (Ferrari et al. 2015). The CDC has recommended
that SCT screening programs have policies to protect an indi-
vidual’s privacy (Grant et al. 2011). This is critical to respect
the person and the privacy of health information, and to help
protect student-athletes from stigma and discrimination.
This study revealed potential tensions between athletic staff
who had no buy-in to the 2010 policy and believe they lack
resources and clear directives, and a governing body per-
ceived to be reacting to a lawsuit. As an alternative to a testing
policy some branches of the military have used a system
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called universal precautions; a protocol of supervision and
actions designed to prevent exertional heat illness (EHI) for
everyone in the group exercising. This includes: hourly mon-
itoring of the ambient temperature; decreasing exercise inten-
sity and increasing rest time when temperature reaches 90 ° F;
increasing and monitoring water intake; wearing light-weight
clothing; and beginning cooling and rehydration and monitor-
ing body temperature at the first sign of heat distress (Kark
et al. 2010). The use of universal precautions has had some
success with military recruits (Gardner & Kark 1994; Kark
et al. 1987); however, this system has not eliminated deaths
to which SCT may have been a contributing factor (Ferster &
Eichner, 2012). Despite the tensions and remaining questions,
each staff member we interviewed valued having SCT health
information for student-athletes.
Study Limitations
A limitation of our study is the small sample size. At seven of
the ten participating schools we interviewed only one member
of the athletic staff, so we may not have received complete
information about how they implemented the policy. At the
schools where we interviewed two staff members, we were
able to get a more comprehensive view of implementation
practices. We interviewed head athletic trainers and team phy-
sicians because these staff were most closely involved with
implementation related to the policy; however, this limited our
data to the views of these two staff positions. Qualitative re-
search uses the concept of Bsaturation^ meaning that data
gathering is not yielding any new information. Data saturation
indicates that enough people have been interviewed on that
topic (Guest et al. 2006). Due to the small sample size, some
topics were near saturation of information and others were not.
Topics on which we did not gather enough data we either did
not include in this paper or, if included, we indicated that only
a few participants discussed them.
Secondly, our data may not be generalizable, since they are
only from North Carolina, and implementation of the policy
may differ in other states. Thirdly, it was challenging to con-
duct full-length interviews, given time constraints resulting
from the competing demands of the participants’ athletic
duties. We arranged all interview appointments in advance;
however, participants would often indicate at the beginning
of the interview that they only had a few minutes, and were
often traveling. Due to the topic and specific interview ques-
tions, a few participants seemed defensive about the questions
and this constrained some of their responses.
Conclusions
Despite its limitations, our research uncovered a variety of
issues that need to be addressed to facilitate: 1) the identifica-
tion and safety of all NCAA student-athletes with SCT; 2)
adequate preparation of athletic staff to effectively implement
the NCAASCTscreening policy; and 3) equitable distribution
of resources and infrastructure for schools to support the pol-
icy. Further research is needed to determine the extent to
which the findings from DI schools in North Carolina reflect
perspectives and experiences nationally.
Research Recommendations
Directions for future research include investigations of region-
al differences (e.g., higher versus lower altitude states), differ-
ences between NCAA conferences or divisions, and differ-
ences between types of schools (e.g., Historically Black
Colleges and Universities versus other schools) in terms of
practices (e.g. availability of genetic counseling, educational
materials, waiver use, and the type of SCT tests used) and the
views of a range of key stakeholders including student-
athletes with and without SCT. It is critical to develop a more
complete picture of how the NCAA SCT screening policy
affects schools, staff, and student-athletes in order to maxi-
mize its benefit and minimize its harm.
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